Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.
The immuno-oncology market is projected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, driven by checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, with North America commanding 43% market share.
The global cancer gene therapy market is projected to grow from $3.6 billion in 2023 to $16 billion by 2033 at a 16.1% CAGR, while the broader oncology market eyes $748 billion by 2035, driven by immunotherapy advances and targeted treatments.
The global oncology market is projected to nearly triple from $279.98 billion in 2026 to $748.17 billion by 2035, driven by rapid adoption of immunotherapy, checkpoint inhibitors, and cell therapies across solid tumors and hematologic cancers.
Researchers unveil pancreatic-targeted lipid nanoparticles using capsule filtration mechanisms, while a contract research organization expands lipid-based vector development services for organ-selective mRNA delivery.
